Status:
COMPLETED
Treatment of Adult ALL With an MRD-directed Programme.
Lead Sponsor:
Northern Italy Leukemia Group
Collaborating Sponsors:
Associazione Italiana per la Ricerca sul Cancro
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
15-65 years
Phase:
PHASE2
Brief Summary
The study aims to optimize the concept of risk-oriented postremission consolidation therapy, by offering (i) standard consolidation-maintenance to patients at lowest risk of relapse as defined by MRD(...
Detailed Description
Improved outcome of adult ALL through the application of: * Risk-adapted induction (cycle no. 1: IVAP i.e idarubicin-vincristine-asparaginase-prednisone, plus fractionated cyclophosphamide in T-ALL,a...
Eligibility Criteria
Inclusion
- Untreated Acute lymphoblastic leukemia or lymphoblastic lymphoma (T-cell, precursor B-cell)
- Age 15-65 years (older patients if biologically fit according to responsible physician)
- Written informed consent
Exclusion
- Any co-morbidity precluding the administration of intensive chemotherapy for adult ALL
Key Trial Info
Start Date :
May 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00358072
Start Date
May 1 2000
End Date
September 1 2008
Last Update
December 29 2010
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedali Riuniti di Bergamo
Bergamo, BG, Italy, 24128
2
Divisione Ematologia Spedali Civili
Brescia, BS, Italy, 25123
3
Divisione di Ematologia e TMO Ospedale San Maurizio
Bolzano, BZ, Italy, 39100
4
U.O. Ematologia e Centro TMO Ospedale Armando Businco
Cagliari, CA, Italy, 09121